MTP to develop EnVivo's lead candidate in Asia
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) has licensed in rights for Japan and other Asian markets to EnVivo Pharmaceuticals' lead product candidate EVP-6124. The oral alpha-7 nicotinic acetylcholine receptor agonist is being developed for cognitive impairment associated with Alzheimer's disease and schizophrenia.